An Observational Study to Evaluate the Effect of Vildagliptin Compared to Glimepiride on Glycemic Control and Lipemia in Type 2 Diabetes Patients

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which can lead to complications such as cardiovascular disease, neuropathy, retinopathy, and nephropathy. T2DM typically arises in adults due to insulin resistance or insufficient insulin secretion. This study aims to compare the effects of vildagliptin, a DPP-4 inhibitor, with glimepiride, a sulfonylurea, on glycaemic control and lipid profiles in patients with T2DM. A prospective, comparative study was conducted at Durgabai Deshmukh Hospital, Hyderabad, In General Medicine Department following ethical approval. A total of 80 patients with T2DM were enrolled, with 40 patients receiving glimepiride therapy and 40 patients receiving vildagliptin therapy. Clinical and biochemical parameters, including fasting blood glucose , Postprandial blood glucose , HbA1c, body mass index (BMI), and lipid profile, were measured at baseline and after the intervention. The results found to be statistically significant. A 90% favourable clinical outcome was observed in vildagliptin treated patients, with the most pronounced reductions in BMI and HbA1c among patients aged 60–70 years and in female patients.Vildagliptin significantly improved glycaemic control, reduced glycaemic and lipid variability, and presented a lower risk of hypoglycemia compared to glimepiride. These findings suggest that vildagliptin may provide long-term benefits in reducing the risk of complications associated with T2DM.